| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 75.60 | 101.5% | 5.0% |
| Total Income | 76.52 | 101.0% | 13.6% |
| Expenditure | 66.92 | 214.4% | 37.5% |
| PBT | 9.60 | 42.8% | 48.6% |
| Net Profit | 7.15 | 44.1% | 44.7% |
| OPM | 12.72% | 32.94pp | 27.19pp |
| NPM | 9.34% | 24.28pp | 9.84pp |
| EPS | 1.98 | 50.1% | 65.3% |
One listing, no margin cushion—and the market pricing in four more
Gretex delivered just one IPO in Q2 against guidance of 3–4, halving margins to 12.7%. Yet the stock trades near its all-time high, betting entirely on the four DRHP mandates and a strategic pivot to recurring advisory that's still unproven.
₹7.1 Cr
−44.7% YoY
₹19.9 Cr
+43.2% YoY
₹13 Cr
₹1.5 Cr vs. −₹11.5 Cr prior year
12.7%
−27.1pt YoY
The headline reads like a collapse: Q2 profit down 45%, margins halved. But the real story is simpler—and riskier. Gretex delivered one IPO listing (Vama Wovenfab in September) against guidance of at least three to four. That single miss explains both the revenue decline and the margin fall. The market, however, is pricing in redemption: the stock trades near its all-time high of ₹800.8, betting that four DRHP-approved mandates will close in Q3 or Q4, and that a nascent pivot to recurring advisory revenue will eventually stabilize the lumpy deal-driven model. Neither assumption has been proven yet.
The H1 PAT story: reported vs. organic
The first half shows PAT growth of 43.2%, which looks like relief after Q2. But dig into the composition, and the picture shifts: H1 other income was ₹1.5 Cr against negative ₹11.5 Cr in the prior year—a ₹13 Cr favorable swing. Exclude that, and core operational profit is essentially flat YoY. Q2 itself carries no such cushion; it is the miss laid bare.
What management said vs. what held up
Margin decline is only about lower turnover, not weakness
Correct: EBITDA margin fell 27.1 points due to one listing vs. expected ≥3–4. But evasive—the real risk is that the model is structurally lumpy; fewer mandates compress absolute margin cover.
Supported (but incomplete)
H1 PAT up 43.2%; solid operational progress
Inflated by ₹13 Cr other-income swing. Core operational PAT flat YoY. Not recurring.
Overstated
Building integrated capital markets business; post-listing advisory, AIF expansion
Articulated strategy; early execution (₹25 Cr AIF first close, Ahmedabad broking office, one preferential issue mandate). Highly conceptual; no revenue run-rate or ROI targets provided.
Partial
Primary market strong; ₹84,400 Cr mainboard fundraising in H1 FY27
Industry fact verified (+30% YoY, 71 mainboard IPOs vs. 55). But Gretex's core competency (SME segment) weakened: 137 SME listings (−12%) and ₹6,012 Cr fundraising (−11% YoY).
Supported (but context matters)
What changed on this call
IPO execution velocity downgraded: Q1 expected ≥3–4 Q2 listings; delivered 1 (Vama Wovenfab, Sep 22). 4 DRHP mandates filed but not closed; pipeline pushed to Q3–Q4.
Strategic pivot announced: Shift from transaction-led to recurring revenue (post-listing advisory retainers targeting ₹10 lakhs–₹1 crore monthly per client; AIF participation). First ₹25 Cr fund (Celestial Chakra Momentum) closed. Nascent; unquantified aggregate.
Segment exposure rebalancing: Mainboard IPOs strong (+30% fundraising, 71 listings H1 FY27). SME segment (Gretex's core) moderated (−12% listings, −11% fundraising). Gretex executed 1 SME listing; 4 mainboard mandates pending.
Margin sustainability risk heightened: EBITDA margin 39.8% (Q2 FY26, 16+ deals) → 12.7% (Q2 FY27, 1 deal). Structural lumpy-ness exposed; absolute margin cover halved.
The bull-bear ledger
Industry tailwind intact: Primary market strong (₹84,400 Cr mainboard raised H1 FY27, +30% YoY). Record fundraising environment creates runway for executed mandates.
Pipeline credibility in doubt: Q2 guidance of ≥3–4 listings missed; 1 delivered. 4 DRHP mandates cite 'maybe this quarter or next,' not certainty. Guidance credibility eroded.
Core SME segment weakness: SME IPO fundraising −11% YoY to ₹6,012 Cr. Gretex's historical strength vulnerable to competitive intensity and investor selectivity. Shift to mainboard adds scale risk (longer execution, lower fees per rupee raised).
Recurring revenue unproven at scale: Post-listing advisory and AIF strategies conceptually sound but early-stage. No revenue run-rate, cost base, or breakeven timeline disclosed. Transition risk material.
H1 momentum masks Q2 deterioration: H1 revenue +11.4% YoY and H1 PAT +43.2% (other-income inflated). Q2 in isolation: revenue −5%, PAT −44.7%. Sequential quarter-on-quarter collapse in profit (−44.1% QoQ PAT) despite +101.6% revenue QoQ recovery.
Risks, ranked by how much they should concern a holder
Deal pipeline execution slippage (4 DRHP mandates) and no closure guarantee
HighQ2 missed ≥3–4 guidance badly (delivered 1). 4 DRHP mandates (Sky, Tenty, Abacus, Oremet) remain pending with only 'maybe this quarter or next' visibility. A 3–6 month delay pushes material revenue into H2 FY27 or even FY28, impacting FY27 consensus and extending margin pressure.
Lumpy, deal-dependent revenue and margin volatility; structural not cyclical
HighEBITDA margin collapsed 27.1 points (39.8% → 12.7%) from one listing shortfall. Absolute margin cover halved. Recurring advisory and AIF are nascent. If the deal model cannot be stabilized by recurring revenue within 12–18 months, valuation multiple re-rating downward becomes likely.
SME IPO segment moderation; competitive intensity and pricing pressure
MediumH1 FY27 SME fundraising −11% YoY to ₹6,012 Cr (137 listings vs. 156). Gretex's core competency vulnerable. Shift to mainboard (4 pending mandates) adds execution complexity and may lower fee margins per rupee raised despite larger deal sizes.
Other income volatility masks core profit weakness
MediumH1 other income ₹1.5 Cr vs. −₹11.5 Cr prior year (₹13 Cr favorable swing). Inflated H1 PAT by ≈₹13 Cr. Not recurring. Q2 carries no such cushion. If other income normalizes, FY27 PAT could disappoint consensus.
Recurring revenue model unproven; no quantified run-rate or ROIC
Medium–HighPost-listing advisory targeting ₹10 lakhs–₹1 crore monthly per client (unquantified aggregate), and AIF participation (₹25 Cr first close, ₹50+ Cr target corpus). No revenue timeline, cost base, or breakeven. Transition risk high; new revenue streams could be delayed or underdeliver.
How the market is positioned
The stock trades at ₹783, just 2.2% below its all-time high of ₹800.8, with an RSI of 73.9 (overbought territory). This is a bullish bet on execution. Over the past year, the stock has rallied +245.7% from its 52-week low of ₹226.5, and it sits well above its 20-day (₹753.69) and 50-day (₹679.67) averages—classic strong-trend structure. Yet the quarter itself was a miss: guidance for ≥3–4 listings, delivered 1. The valuation move suggests the market has already priced in the four DRHP closures and the pivot to recurring advisory. There is little room for further disappointment without a sharp pullback.
Ownership tells a cautious story: FII holdings rose 0.89 percentage points to 1.99% in Q1 FY27 (from 1.10% in Q4 FY26), a modest incremental buy. Promoter stake remains steady at 61.64%. Domestic institutional investors (DII) are absent (0.00%). In the bulk/block deals over the past six months, Mansukh Securities has dominated activity—trading volume in late October 2026 near the highs (₹723–₹737 range) suggests tactical long-short flows rather than strategic institution conviction. The pattern—small FII buy-ins, promoter hold steady, tactical shorting near highs—implies that smart money is waiting for Q3–Q4 pipeline delivery before committing capital. The market's bullish price structure masks underlying caution.
The debate
What to watch next
1 · Q3–Q4 DRHP listing closures (Sky, Tenty, Abacus, Oremet)
If 2+ mandates close in Q3, expect EBITDA margin to recover toward 25–30% and PAT to rebound materially. Each closure is binary; no closure by Dec 31, 2026 signals either execution failure or deeper market headwinds, prompting consensus cuts and re-rating risk.
2 · Post-listing advisory retainer revenue run-rate and AIF 2nd close
Post-listing mandates must show traction (retainer customers, monthly fee run-rate) by end-H1 FY27 Q4 results (Sep 2027). The ₹25 Cr first close is a start; a ₹50+ Cr target corpus 2nd close signals investor confidence and materially de-risks the recurring-revenue transition. Absence of progress on both fronts will be read as execution risk on the strategic pivot.
3 · FY27 and FY28 guidance revision (revenue, PAT, margin targets)
Management has given no quantified targets. By Q3 results, revised FY27 guidance and an FY28 revenue/margin outlook are necessary to repair credibility post-miss. If guidance remains unquantified, it signals management confidence deficit or intentional caution—either way, a red flag for execution.
Gretex is a step-change transformation in progress, not a steady franchise. Q2 was not a blip; it was the fragility of the deal-dependent model laid bare. The market is pricing in perfect execution on four pending mandates and a successful early-stage pivot to recurring advisory—both of which are uncertain. The stock has priced in the upside; the downside risk is material if closures slip or strategic initiatives disappoint. The number to track from here is the Q3–Q4 listing tally and the early run-rate of post-listing advisory retainer revenue. Execution must now happen. The call for strategic investors remains Hold pending clarity on the pipeline and momentum on recurring revenue. For tactical traders, the overbought technicals (RSI 73.9, near ATH) argue for waiting for a pullback to the 50-day moving average (₹679.67) or a concrete catalyst (a listed mandate) before re-entry.
Execution miss overshadows industry tailwind; margins halved on low deal volume
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Missed Q2 listing guidance (1 vs. ≥3–4 expected). H1 PAT growth inflated by ₹13Cr other-income swing; core operational PAT flat.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Revenue -5% YoY, PAT -44.7%, EBITDA margin collapsed 27 points on single listing vs. expected 3–4 closures. Industry is strong (mainboard +30% fundraising) but Gretex missed execution and core SME segment weakened. Forward pipeline (4 mandates) and strategic pivot to recurring advisory/AIF are promising but unquantified; no PAT or margin targets offered. Execution risk remains high.
₹75.6 Cr
Revenue · −5% YoY₹7.1 Cr
Reported PAT · −44.7% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
One listing completed; most mandates delayed
MISSVama Wovenfab delivered Sep 22, 2026. 4 DRHP approvals (Sky, Tenty, Abacus, Oremet) pending — 0 executed this quarter
Only reason for margin decline is lower turnover, not fundamental weakness
METCorrect: EBITDA margin fell 27 points (39.8%→12.7%) due to single listing vs. expected multiple closures. But guided ≥3–4 listings; delivered 1. Operational model is inherently lumpy.
H1 shows 43.2% PAT growth
OVERSTATED₹19.9 Cr vs ₹13.9 Cr H1 FY26 = +43.2%. But inflated by ₹1.5 Cr other income vs. -₹11.5 Cr prior year. Core PAT lift is ~₹6.1 Cr on no revenue growth — margin-driven, not sustainable.
Primary market demonstrated considerable resilience; record ₹84,400 Cr mainboard fundraising in H1 FY27
METIndustry fact verified. 71 mainboard IPOs vs. 55 H1 FY26. But SME segment declined: 137 listings vs. 156, fundraising down 11% to ₹6,012 Cr. Gretex's core competency (SME) weakened.
Building integrated capital markets business; post-listing advisory, AIF, future mandates
PartialArticulated strategy; early execution (₹25 Cr first close, Ahmedabad broking office, 1 preferential issue). Highly conceptual; no revenue run-rate or ROIC targets provided.
Earnings quality
What changed since the last call
IPO execution velocity
DowngradeQ1 FY27 call expected 3–4 Q2 listings. Delivered 1 (Vama). 4 DRHP filed but no mainboard closures in Q2. Deal pipeline pushed to Q3–Q4.
Strategic business model
NewAnnounced shift from transaction-led to recurring revenue (post-listing advisory, AIF participation). First ₹25 Cr fund close completed. No prior call mentioned alternative investments.
Market segment exposure
NeutralH1 FY27: mainboard +30% fundraising (₹84,400 Cr), SME segment -11% (₹6,012 Cr). Gretex executed 1 SME listing; 4 mainboard mandates in pipeline. Rebalancing toward larger deals.
Margin sustainability
DowngradeEBITDA margin 39.82% (Q2 FY26) → 12.7% (Q2 FY27). Management attribution: lower deal volume. Structural risk: fewer mandates → lower absolute margin cover.
The Q&A
Minimal analyst pressure. Only 2 substantive questions: (1) margin decline — management deflected to turnover difference, correct but evasive; (2) pipeline — management cited 4 approvals pending. No questions on customer concentration, competitive moat, or recurring-revenue model viability. Call lacked depth.
Margin compression — Unnamed, chat-submitted
PartialNo decline in margin itself; decline in turnover. Only 1 listing done vs. prior expectations. Lower turnover = lower margin.
Transaction pipeline — Diptesh Kanoria
Answered4 approvals in hand, supposed to be listed. Expect listings this quarter or next quarter.
Guidance
No explicit FY27 or H2 FY27 revenue target provided
LowManagement cited 4 pending listings and stated expectation of closures 'this quarter or next.' Unquantified revenue impact.
No margin targets provided; acknowledged volatility tied to deal timing
LowQ2 EBITDA margin 12.7% attributed to low deal volume. Strategic pivot to recurring advisory may improve stability long-term, unquantified.
Risks the call surfaced
Execution and pipeline
HighQ2 delivered 1 listing vs. expected 3–4. 4 DRHP mandates pending; no guaranted Q3 closure. Delay pushes material revenue into H2 FY27.
Business model sustainability
HighEBITDA margin collapsed from 39.8% (Q2 FY26, 16+ deals) to 12.7% (Q2 FY27, 1 deal). Absolute margin cover halved. Recurring advisory and AIF strategies unproven at scale.
Segment exposure
MediumH1 FY27 SME IPO fundraising down 11% YoY to ₹6,012 Cr (137 listings vs. 156). Mainboard strong (+30%, 71 listings) but higher deal size, longer execution, lower fee per ₹ raised likely.
Other income volatility
MediumH1 FY27 other income ₹1.5 Cr vs. -₹11.5 Cr H1 FY26 = ₹13 Cr swing. Inflated H1 PAT growth to +43.2%; core operational PAT likely flat. Not sustainable or repeatable.
Management
Score 5/10. Transparent on deal timing and market headwinds (SME moderation). Deflective on margin decline (blamed turnover, correct but evasive). No customer concentration, competitive moat, or cost structure detail. Mixed. H1 revenue +11.4% on track, but Q2 missed listing guidance badly (1 vs. ≥3–4). H1 PAT +43.2% but inflated by other-income swing; core ops weak. Strategic pivot to recurring advisory and AIF articulate but unproven.
1 · Q3 FY27
4 DRHP mandates listed; Sky Alloys, Tenty, Abacus Lifestyle, Oremet Alloys expected closures
2 · H2 FY27
AIF/alternative investment advisory expansion; 2nd close of Celestial Chakra fund targeting ₹50+ Cr corpus
3 · FY28
Post-listing advisory retainer revenue stream maturation; targeting ₹10 lakhs–₹1 crore per client monthly
Execution risk remains high.